Meta Pixel

Novapep

Australia|Biotechnology

Overview

Novapep, an Australian/US biotech, has developed a patented peptide structure called biparetideTM as an oral inflammatory bowel disease (IBD) therapy, which will be a cost effective, first-in-class drug. Biparetide has been shown in animals to be as effective as expensive, injectable biologic drugs (the gold standard) and superior to corticosteroids, but with minimal expected side effects. 

Novapep’s co-founders, Prof John Griffin and Prof Laurent Mosnier at the Scripps Research Institute in San Diego and Prof Chris Jackson at the University of Sydney have conducted over 15 years of ground breaking R&D in Activated Protein C (APC), which is anti-inflammatory, protects against unprogrammed cell death and has been shown to be effective in treating numerous diseases including inflammatory skin disorders and IBD. However, APC is very expensive to manufacture, needs to be stored at -70 C and is only being developed for high dose, intravenous administration in stroke and amyotrophic lateral sclerosis.

In response to APC's shortcomings, Novapep’s scientists invented a peptide structure called biparetide, which is a mimetic of APC, is more than an order of magnitude cheaper to manufacture and is stable at room temperature. The composition of matter patent for this invention was filed in 2019, which provides IP protection to 2039, with likely follow on patents, and it was licensed by Novapep from the Scripps in August, 2021. Novapep has previously raised ~$1,000,000 to optimise the molecule and conduct a number of animal studies demonatrating the efficacy of biparetide.

Novapep started a $1,000,000 equity capital raise in February and $350,000 has been raised to date. This funding will allow Novapep to progress its IBD program towards a Phase 1 clincial trial targetted to start at the end of 2025. Discussions are also underway with big pharma with the aim of concluding a partnering deal.

Problem and Solution

Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet.



Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim. In dui nisl, vestibulum eu finibus pretium, eleifend et eros. Vivamus in venenatis risus, ut dictum velit. Praesent rhoncus tempor fermentum. In malesuada tellus eu volutpat posuere. Nullam ut dignissim libero, ut pharetra leo. Nullam sit amet aliquam felis. Suspendisse volutpat ante eget tincidunt feugiat. Nunc placerat sapien et metus molestie, in viverra augue viverra. Donec varius metus ut arcu vestibulum hendrerit. Sed viverra risus neque, ac commodo enim lacinia at.



Morbi posuere tortor vitae sapien faucibus auctor. Donec nulla ipsum, aliquet non bibendum sit amet, viverra non metus. Sed blandit efficitur orci, id dignissim eros.



Donec sollicitudin massa ut tellus gravida, ut luctus lacus maximus. Maecenas porttitor a tellus ac sagittis. Suspendisse potenti. Donec mauris sem, tristique a ipsum vitae, pretium facilisis libero. Nullam interdum mauris in euismod pretium. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Nunc felis lectus, ornare a nunc eu, convallis suscipit elit. Donec at magna non


Open an account to get
access to more details

Market Opportunity

Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.



Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.



Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.

Aenean lacinia id quam a lobortis. Cras nibh lorem, vulputate eget purus elementum, pharetra condimentum elit.



Quisque et sagittis ex, vitae ultrices nulla. Vivamus dapibus blandit libero, et scelerisque dui ullamcorper ut. Vivamus ut molestie ex. Integer eget tempus maur


Open an account to get
access to more details

Competitive Advantages

Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.



Duis vitae mi neque. Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.

Proin neque lacus, semper vel ex at, eleifend rhoncus est.

Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a.
Nullam fringilla diam eget dui placerat fermentum. Maecenas malesuada viverra leo eu bibendum. Nam vulputate enim velit, eu pretium justo tristique ac.


Nam vitae varius augue. Nam pharetra facilisis elementum. Sed nisl ris


Open an account to get
access to more details

Highlights & Milestones

Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet.



Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim. In dui nisl, vestibulum eu finibus pretium, eleifend et eros. Vivamus in venenatis risus, ut dictum velit. Praesent rhoncus tempor fermentum. In malesuada tellus eu volutpat posuere. Nullam ut dignissim libero, ut pharetra leo. Nullam sit amet aliquam felis. Suspendisse volutpat ante eget tincidunt feugiat. Nunc placerat sapien et metus molestie, in viverra augue viverra. Donec varius metus ut arcu vestibulum hendrerit. Sed viverra risus neque, ac com


Open an account to get
access to more details

See more exiting opportunities on CapitalHQ

BetterX

BetterX offers B2B and B2B2C white-label and API driven software solutions to traditional institutions to offer digital asset services to their clients.

flag_australia
Australia AUD
Fintech Seed Round

Paycepaid

Paycepaid is a Software as a Service debt collection solution unlike any on the market today with a heavy focus on the debtor. Empowering businesses to manage their end to end collections while providing debtors with a magnitude of options to reduce financial stress and anxiety.

flag_australia
Australia AUD
Online Marketplace Seed Round

Wholesale Investor

Wholesale Investor, with over 45,000 subscribers, is a leading private capital marketplace operating across Australia, Singapore, and the UK. It has a 15-year track record of connecting private market opportunities with HNW, professional, and family office investors. In just 4 years, our product...

flag_australia
Australia AUD
Fintech Series B+ Software-as-a-Service

PRIMAL ORGANIX

Primal Organix has created the world’s first botanically derived Terpene blended anti-anxiety health supplement that manages anxiety in minutes. Our purpose is to support positive mental ill-health and well-being in all human beings.

flag_australia
Australia AUD
Healthcare Series A

Sustainable Fintech Fund

Startupbootcamp, the #1 Accelerator in the world outside of the US, established in 2010, operates in 27 countries around the globe, has accelerated over 1600+ startups with a success rate of 76% remaining active, raised over $2.2B in total funding, a network of more than 300+ investors, 5000...

flag_australia
Australia AUD
Fintech Fund

Misio

Sustainability performance and stakeholder communications are now fundamental to overall corporate profitability and impact. Misio simplifies a complex eco-system to help large & listed companies shift the sustainability narrative out from annual reports into easy to understand digital...

flag_australia
Australia AUD
Sustainability Bridging Round

Pictor

Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,...

flag_new zealand
New Zealand NZD
Biotechnology Series B+

National Property Group

National Property Group (NPG) is a trusted alternative provider of property data and insights empowering informed decisions for all property market participants. NPG relaunched its property data & analytics intelligence platform in 2021, delivering instant insights from more than 40 years of...

flag_australia
Australia AUD
Proptech Series B+

Novapep

Novapep, an Australian/US biotech, has developed a patented peptide structure called biparediteTM as an oral inflammatory bowel disease therapy, which will be a cost effective first-in-class drug. Biparetide has been shown in animals to be as effective as expensive, injectable biologic drugs (a...

flag_australia
Australia AUD
Biotechnology Seed Round

Join over 45,000+ sophisticated investors

Join Now